Pain Management

The Mitragynine Urine Drug Screen with Confirmation screens for the kratom alkaloid mitragynine in urine, then applies confirmatory testing to validate positive findings. This two-step process enhances accuracy and specificity, helping clinicians and monitoring programs reliably identify kratom use with both detection and verification of mitragynine presence.

The Naltrexone Urine Drug Test quantitatively measures the concentration of naltrexone and its metabolites in urine using sensitive analytical techniques. This detailed assay provides numeric levels rather than just detection, supporting clinicians and monitoring programs in assessing adherence, dosage exposure, and treatment response. It helps distinguish low-level presence from medically relevant levels.

The Opiates Urine Drug Screen detects the presence of opiate compounds (such as morphine, codeine, and related metabolites) in urine above predetermined cutoff levels using immunoassay methods. This screening test offers an initial detection of opiate use in clinical, monitoring, or treatment settings. Positive results indicate detection above threshold, but this version does not include confirmatory testing.

The Opiates Urine Drug Screen with Confirmation begins with immunoassay screening for opiate compounds (such as morphine, codeine, hydrocodone), then validates positive results using confirmatory methods. This two-step process ensures specificity and reduces false positives, delivering reliable confirmation of opiate detection in urine for clinical, legal, or monitoring settings.

The Oxycodone Urine Drug Screen detects the presence of oxycodone and related metabolites in urine above established cutoff levels using immunoassay screening. This test provides an initial indication of opioid exposure in clinical, treatment, or monitoring settings. A positive result signals detection beyond threshold, but confirmatory testing is not included in this version.

The Oxycodone Urine Drug Screen with Confirmation begins with an immunoassay screen for oxycodone and its metabolites in urine, then uses confirmatory testing (e.g. mass spectrometry) to validate positive results. This two-step process enhances specificity and reduces false positives, offering reliable confirmation of oxycodone exposure in clinical and monitoring settings.

The Panel 3 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening, with positive results verified by advanced confirmatory methods. This two-step process enhances accuracy by minimizing false positives and provides reliable insight into substance exposure. It is suited for clinical, workplace, and monitoring applications requiring dependable results.

The Panel 4 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening, then verifies positive findings using confirmatory analysis. This two-step process enhances specificity and reduces false positives, providing dependable insight into substance exposure for clinical, monitoring, or workplace applications.

The Panel 5 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and validates positive findings through confirmatory analysis. This dual-step approach reduces false positives and improves specificity, offering a more trustworthy evaluation of substance exposure in clinical, monitoring, or workplace contexts.

The Panel 5 Urine Drug Screen with Confirmation and D/L Isomers detects multiple commonly abused drugs in urine via immunoassay screening and verifies positive findings. It further differentiates D- and L-isomer forms of amphetamines to improve specificity and interpretive clarity. This multi-step analysis supports accurate results in clinical, workplace, and monitoring settings.

The Panel 7 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and then validates positive results through confirmatory testing. This two-step approach increases specificity by reducing false positives, providing dependable insight into exposure to an extended panel of substances in clinical, monitoring, or workplace settings.

The Panel 8 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening and validates positive results using confirmatory analysis. This two-step method enhances specificity and reduces false positives, providing reliable insight into substance exposure across a broader panel of substances in clinical, workplace, and monitoring environments.

The Phencyclidine Urine Drug Test quantitatively measures phencyclidine (PCP) concentration in urine using high-precision mass spectrometry. This definitive analysis provides exact numeric values—not just detection—helping clinicians distinguish trace exposure from significant use and supporting monitoring or forensic contexts with clarity and accuracy.

The Phencyclidine Urine Drug Screen detects PCP (phencyclidine) and its metabolites in urine using immunoassay screening above defined cutoff levels. This test offers an initial assessment of PCP exposure in clinical, monitoring, or treatment settings. Detection suggests recent use, but this version does not include confirmatory testing, so positive results should be interpreted with caution.

The Phencyclidine Urine Drug Screen with Confirmation begins with a sensitive immunoassay screen for PCP and then reflexes positive findings to confirmatory testing (LC/MS/MS) for validation. This two-step process reduces false positives and ensures reliable detection of PCP use in urine for clinical, forensic, or monitoring purposes.

The Pregabalin Urine Drug Test quantitatively measures concentrations of pregabalin in urine using precise analytical methods, supporting clinical and treatment monitoring. This quantitative assay provides clear numeric levels rather than a simple positive/negative result, helping clinicians distinguish between low-level presence and meaningful dosing patterns, and assess compliance or exposure over time.

The Propoxyphene Urine Drug Test quantitatively measures propoxyphene and its metabolite levels in urine using mass spectrometry methods. This precise assay reports numeric concentrations, enabling clinicians and monitoring programs to assess exposure, distinguish therapeutic levels from misuse, and observe patterns over time — offering more depth than a simple detection screen.

The Propoxyphene Urine Drug Screen detects propoxyphene and its metabolites (such as norpropoxyphene) in urine above defined cutoff levels using immunoassay screening. This test offers initial detection of propoxyphene exposure in clinical or monitoring settings. A positive result signals presence beyond threshold, but this version does not include confirmatory testing.

The Propoxyphene Urine Drug Screen with Confirmation begins with an immunoassay screen for propoxyphene and its metabolites, then uses confirmatory testing (e.g. mass spectrometry) to validate positive results. This two-step approach improves specificity, ensuring that detected propoxyphene in urine is verified—ideal for clinical, forensic, or monitoring contexts where result accuracy is critical.

The Tapentadol Urine Drug Test quantitatively measures tapentadol and its metabolites in urine using advanced analytical techniques. This assay provides precise concentration values—rather than just presence—helping clinicians and monitoring programs gauge exposure levels, differentiate trace from significant use, and track individual usage patterns over time.

The Tramadol Urine Drug Test quantitatively measures tramadol and its metabolite concentrations in urine using precise analytical methods. This detailed test provides numeric values beyond simple detection, supporting clinicians and monitoring programs in assessing exposure levels, compliance, and usage trends over time.

The Tricyclic Antidepressants Urine Drug Test quantitatively measures levels of common TCAs and their metabolites in urine using advanced laboratory methods. By providing exact concentration values, this test supports clinicians in assessing exposure, monitoring therapeutic use, and distinguishing compliance from potential misuse or toxicity in clinical and monitoring settings.

The Zolpidem Urine Drug Test quantitatively measures zolpidem levels in urine using precise laboratory techniques. This test provides exact concentration values rather than a simple presence or absence, helping clinicians assess exposure, monitor therapeutic use, and evaluate compliance or misuse. Quantitative results give a clearer picture of recent zolpidem intake patterns for accurate monitoring.

 The Quantitative Methadone Serum test is a specific blood test used to determine the concentration of methadone in the blood. Methadone is a synthetic opioid analgesic that is often prescribed for pain management and, more commonly, for the treatment of opioid dependence, particularly heroin addiction. By quantifying the amount of methadone in the serum, healthcare providers can monitor compliance with treatment, assess potential toxicity, and aid in the interpretation of clinical presentations related to methadone use.